Status:
SUSPENDED
Angiotensin II for Septic Shock Treatment
Lead Sponsor:
Cairo University
Conditions:
Septic Shock
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This study aims to investigate the effect of angiotensin II on microcirculation and peripheral perfusion in patients with septic shock.
Detailed Description
Shock is a syndrome characterized by acute circulatory failure resulting in impaired peripheral tissue perfusion. Distributive shock is the most common type of shock and is usually caused by severe se...
Eligibility Criteria
Inclusion
- Septic shock patients.
- Aged above 18 years.
- With cardiac index \> 2.4 L/min/BSA 1.73 m2.
- On high dose vasopressors (defined as norepinephrine infusion above 0.1 mcg/Kg/min)
Exclusion
- Acute coronary syndrome.
- Impaired cardiac contractility
- Bronchospasm.
- Major burns
- Liver failure.
- Active bleeding.
Key Trial Info
Start Date :
April 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 15 2019
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03302650
Start Date
April 1 2019
End Date
August 15 2019
Last Update
January 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Egypt